WallStSmart
ALLO

Allogene Therapeutics Inc

NASDAQ: ALLO · HEALTHCARE · BIOTECHNOLOGY

$2.13
+0.95% today

Updated 2026-04-30

Market cap
$794.59M
P/E ratio
P/S ratio
7,784.36x
EPS (TTM)
$-0.87
Dividend yield
52W range
$1 – $4
Volume
10.3M

Allogene Therapeutics Inc (ALLO) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item201720182019202020212022202320242025
Revenue$0.00$0.00$0.00$38.34M$38.49M$243000.00$95000.00$22000.00$0.00
Revenue growth (YoY)+0.4%-99.4%-60.9%-76.8%-100.0%
Cost of revenue$0.00$1.50M$5.03M$11.54M$13.06M$16.73M$14.20M$13.64M$12.36M
Gross profit$0.00$-1.50M$-5.03M$-11.54M$38.49M$243000.00$95000.00$22000.00$-12.36M
Gross margin-30.1%100.0%100.0%100.0%100.0%
R&D$151.86M$151.86M$144.53M$192.99M$220.18M$256.39M$242.91M$192.30M$150.15M
SG&A$24000.00$40.98M$57.47M$65.26M$74.11M$79.31M$71.67M$65.20M$56.78M
Operating income$-2000.00$-192.84M$-202.01M$-258.24M$-255.79M$-335.45M$-327.74M$-273.20M$-206.93M
Operating margin-673.5%-664.6%-138044.9%-344986.3%-1241813.6%
EBITDA$22000.00$-206.76M$-179.90M$-250.66M$-245.34M$-321.15M$-313.07M$-243.33M$-194.57M
EBITDA margin-653.7%-637.4%-132162.1%-329543.2%-1106031.8%
EBIT$-2000.00$-208.26M$-184.93M$-258.24M$-255.79M$-335.45M$-327.26M$-256.97M$-206.93M
Interest expense$0.00$3.36M$5.03M$9.16M$10.45M$17.11M$17.11M$181000.00$1.07M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-2000.00$-211.50M$-184.59M$-233.47M$-244.84M$-329.81M$-327.26M$-257.59M$-190.89M
Net income growth (YoY)-10575150.0%+12.7%-26.5%-4.9%-34.7%+0.8%+21.3%+25.9%
Profit margin-608.9%-636.1%-135726.3%-344489.5%-1170863.6%